Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18476728 | 0.98 | LMNA (0.51) | LMNAMAPTSTING1TP53EPHX2 | |
| SCHEMBL18476730 | 0.98 | LMNA (0.51) | LMNAMAPTSTING1TP53EPHX2 | |
| SCHEMBL22504349 | 0.98 | LMNA (0.51) | LMNAMAPTSTING1TP53EPHX2 | |
| SCHEMBL23394749 | 0.98 | LMNA (0.51) | LMNAMAPTSTING1TP53EPHX2 | |
| SCHEMBL27971705 | 0.95 | LMNA (0.54) | LMNAMAPTSTING1TP53MEN1 | |
| SCHEMBL14206944 | 0.87 | LMNA (0.58) | LMNAMAPTSTING1TP53MEN1 | |
| SCHEMBL2097554 | 0.83 | LMNA (0.53) | LMNAMAPTSTING1MEN1ALDH1A1 | |
| SCHEMBL2096337 | 0.81 | LMNA (0.51) | LMNAMAPTSTING1TP53MEN1 | |
| SCHEMBL2096072 | 0.81 | LMNA (0.54) | LMNAMAPTSTING1MEN1ALDH1A1 | |
| SCHEMBL2056126 | 0.80 | LMNA (0.61) | LMNAMAPTSTING1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395510-A1 | Nucleotide Analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OFFICE OF THE GENERAL COUNSEL (024) | 2022-12-15 | — | — | US | disclosed |
| US-11344555-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-11014950-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200316076-A1 | Nucleotide Analogs | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-10-08 | — | — | US | disclosed |
| US-10377782-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-01-18 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-5145975-A | Parasiticides | THE ROCKEFELLER UNIVERSITY (US) | 1992-09-08 | — | — | US | disclosed |
| US-4942170-A | PARASITICIDES, ANTIPROTOZOA AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 1990-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377782-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | LMNA 1406/4885MAPT 4876/4885STING1 121/4885 |
| US-20200316076-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | LMNA 1406/4885MAPT 4876/4885STING1 121/4885 |
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | LMNA 1406/4885MAPT 4876/4885STING1 121/4885 |
| US-11014950-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | LMNA 1406/4885MAPT 4876/4885STING1 121/4885 |
| US-20220395510-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | LMNA 1406/4885MAPT 4876/4885STING1 121/4885 |
| US-11344555-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | LMNA 1406/4885MAPT 4876/4885STING1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.